Amsterdam, The Netherlands – thromboDx, the molecular diagnostics company that develops and commercializes blood-based diagnostics through its proprietary platelet-powered technology platform, announces that is has received another EUROSTARS grant.
Focusing on the development of companion diagnostics for therapy monitoring of lung cancer patients, thromboDx decided to lead a consortium and submit a proposal under the acronym DeltaMET. In DeltaMET the consortium aims to develop a novel diagnostic assay to statify lung cancer patients with EGFR therapy resistance.
The Independent Evaluation Panel for EUROSTARS has reviewed all applications and ranked the DeltaMET-project at position 34 out of 230 eligible project applications, thereby underlining the quality of the proposal and the partners involved.
Besides thromboDx, academic partners Radboud University Medical Center in Nijmegen, the Netherlands and Pangaea Biotech in Barcelona, Spain play an important role in the consortium.
Prof.dr. Thomas Würdinger, Chief Scientific Officer at thromboDx commented: “Receiving funding for this important project yet again demonstrates that the potential of our platelet technology is being acknowledged by independent experts in the field. We are committed to bringing this project to a successful end together with our important partners in Nijmegen and Barcelona.”
thromboDx (www.thrombodx.com) is a molecular diagnostics company that develops and commercializes blood-based companion diagnostics through its proprietary platelet-powered technology platform and has its offices in Amsterdam, The Netherlands. The technology platform addresses the need for an easily accessible, minimally invasive source for high quality disease-specific nucleic acids in several markets.